These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 29956883)

  • 21. Increased frequency of class I and II anti-human leukocyte antigen antibodies in systemic lupus erythematosus and scleroderma and associated factors: a comparative study.
    Tozkir H; Pamuk ON; Duymaz J; Gurkan H; Yazar M; Sari G; Tanrikulu H; Pamuk GE
    Int J Rheum Dis; 2016 Dec; 19(12):1304-1309. PubMed ID: 25292400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis.
    Assassi S; Wu M; Tan FK; Chang J; Graham TA; Furst DE; Khanna D; Charles J; Ferguson EC; Feghali-Bostwick C; Mayes MD
    Arthritis Rheum; 2013 Nov; 65(11):2917-27. PubMed ID: 23897225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
    Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
    Sato S; Nagaoka T; Hasegawa M; Tamatani T; Nakanishi T; Takigawa M; Takehara K
    J Rheumatol; 2000 Jan; 27(1):149-54. PubMed ID: 10648031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial.
    Ebata S; Oba K; Kashiwabara K; Ueda K; Uemura Y; Watadani T; Fukasawa T; Miura S; Yoshizaki-Ogawa A; Yoshihide A; Yoshizaki A; Sato S
    Rheumatology (Oxford); 2022 Nov; 61(11):4364-4373. PubMed ID: 35136981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular damage and lack of angiogenesis in systemic sclerosis skin.
    Konttinen YT; Mackiewicz Z; Ruuttila P; Ceponis A; Sukura A; Povilenaite D; Hukkanen M; Virtanen I
    Clin Rheumatol; 2003 Sep; 22(3):196-202. PubMed ID: 14505210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus.
    Shi ZR; Tan GZ; Meng Z; Yu M; Li KW; Yin J; Wei KH; Luo YJ; Jia SQ; Zhang SJ; Wu J; Mi XB; Wang L
    Arthritis Rheumatol; 2015 Jan; 67(1):193-203. PubMed ID: 25307291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
    Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
    Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients.
    Shi Z; Meng Z; Han Y; Cao C; Tan G; Wang L
    Lupus; 2018 Apr; 27(4):621-627. PubMed ID: 29058991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable difference.
    Li H; Furst DE; Jin H; Sun C; Wang X; Yang L; He J; Wang Y; Liu A
    Arthritis Res Ther; 2018 Aug; 20(1):181. PubMed ID: 30115105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis.
    Arnaud L; Nordin A; Lundholm H; Svenungsson E; Hellbacher E; Wikner J; Zickert A; Gunnarsson I
    Arthritis Rheumatol; 2017 Jun; 69(6):1272-1279. PubMed ID: 28141919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time.
    Skaug B; Lyons MA; Swindell WR; Salazar GA; Wu M; Tran TM; Charles J; Vershel CP; Mayes MD; Assassi S
    Ann Rheum Dis; 2022 Apr; 81(4):516-523. PubMed ID: 34937693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis.
    Yanaba K; Yoshizaki A; Asano Y; Kadono T; Sato S
    J Rheumatol; 2011 Oct; 38(10):2193-7. PubMed ID: 21807780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
    Alexander T; Sarfert R; Klotsche J; Kühl AA; Rubbert-Roth A; Lorenz HM; Rech J; Hoyer BF; Cheng Q; Waka A; Taddeo A; Wiesener M; Schett G; Burmester GR; Radbruch A; Hiepe F; Voll RE
    Ann Rheum Dis; 2015 Jul; 74(7):1474-8. PubMed ID: 25710470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
    Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
    Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.
    Taroni JN; Greene CS; Martyanov V; Wood TA; Christmann RB; Farber HW; Lafyatis RA; Denton CP; Hinchcliff ME; Pioli PA; Mahoney JM; Whitfield ML
    Genome Med; 2017 Mar; 9(1):27. PubMed ID: 28330499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olfactory function in systemic lupus erythematosus and systemic sclerosis. A longitudinal study and review of the literature.
    Bombini MF; Peres FA; Lapa AT; Sinicato NA; Quental BR; Pincelli ÁSM; Amaral TN; Gomes CC; Del Rio AP; Marques-Neto JF; Costallat LTL; Fernandes PT; Cendes F; Rittner L; Appenzeller S
    Autoimmun Rev; 2018 Apr; 17(4):405-412. PubMed ID: 29444467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.